Lilly's next-gen drug tops Zepbound on weight loss in late-stage osteoarthritis trial

Core Insights - Eli Lilly's next-generation obesity drug demonstrated an average weight loss of 28.7% in a late-stage trial, surpassing the performance of its existing drug Zepbound, which solidifies the company's position in the rapidly expanding obesity treatment market [1] Company Summary - The late-stage trial results indicate that Eli Lilly's new obesity drug is more effective than Zepbound, highlighting the company's competitive edge in the obesity drug sector [1] Industry Summary - The obesity treatment market is experiencing significant growth, and Eli Lilly's advancements reinforce its leadership role within this expanding industry [1]